Ferguson GT, et al. - Researchers studied the safety of tiotropium/olodaterol compared with tiotropium in a large population of patients, focusing on cardiovascular and respiratory events by analyzing data of patients who received once-daily tiotropium/olodaterol 5/5 μg or tiotropium 5 μg (via Respimat®) in TONADO 1 & 2 and DYNAGITO. They found that fewer patients discontinued due to adverse events (AEs) with tiotropium/olodaterol vs tiotropium. No significant difference was found in the incidence of AEs, serious AEs (SAEs), cardiovascular AEs or central nervous system vascular AEs between treatments. It was noted that respiratory AEs were generally balanced between treatment groups. According to the findings obtained, the benefits of tiotropium/olodaterol vs tiotropium were not at the expense of an increased risk of safety events. Even in the presence of cardiovascular risk factors, the combination was a suitable option for patients with chronic obstructive pulmonary disease (COPD).